ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
This study provides valuable evidence suggesting the importance of targeting peripheral ANGPTL3 in the anti-PD1/-PDL1 therapy for AGC and will encourage and accelerate the development of a useful biomarker to predict responders/nonresponders to the therapy, leading to improved clinical outcomes in the treatment of gastric cancer.
Authors
- Y. Yamamoto
- Rika Kizawa (ORCID: https://orcid.org/0000-0003-1275-9228)
- H. Imazeki
- Kai Tsugaru (ORCID: https://orcid.org/0000-0001-7763-7999)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Takeshi Kawakami
- Naoki Takahashi
- Chie Kudo-Saito
- Yukiya Narita
- Kei Muro
- Kengo Nagashima
- Narikazu Boku
- Hirokazu Shoji
Institutions
- Kyorin University (JP)
- Shizuoka Cancer Center (JP)
- National Cancer Center (US)
- Keio University Hospital (JP)
- Tokyo Medical University Hospital (JP)
- University of Tsukuba Hospital (JP)
- Chiba Cancer Center (JP)
- Saitama Cancer Center (JP)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- National Cancer Center Hospital East (JP)
- Toranomon Hospital (JP)
- National Cancer Research Institute (GB)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0793
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical